Background: Guidelines and standards for diagnosis and management of chronic obstructive pulmonary disease (COPD) have been presented by different national and international societies, but the spirometric criteria for COPD differ between guidelines. Objectives: To estimate prevalence of COPD using the guidelines of the British Thoracic Society (BTS), the European Respiratory Society (ERS), the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and the American Thoracic Society (ATS). Further, to evaluate reported airway symptoms, contacts with health care providers, and physician diagnosis of COPD in relation to the respective criteria, and gender differences. Method: In 1992 a postal questionnaire was sent to a random sample of adults aged 20–69 years, 4,851 (85%) out of 5,681 subjects responded. In 1994–1995 a random sample of the responders, 970 subjects, were invited to a structured interview and a lung function test; 666 (69%) participated. Results: The prevalence of COPD was 7.6, 14.0, 14.1, 12.2 and 34.1% according to BTS, ERS, GOLD, clinical ATS (with symptoms or physician diagnosis), and spirometric ATS criteria, respectively. Prevalent COPD was related to age, smoking habits and family history of obstructive airway disease but not to gender. Physician diagnosis of chronic bronchitis or emphysema was only reported by 16.3, 12.2, 11.0, 23.4 and 8.2% of subjects fulfilling the respective criteria, though a majority reported airway symptoms. Conclusion: The main determinants for prevalent COPD were age, smoking habits and spirometric criteria of COPD. Though a majority reported airway symptoms and contact with health care providers due to respiratory complaints, only a minority was diagnosed as having COPD, indicating a large underdiagnosis.

Keywords:
Chronic obstructive pulmonary disease, Epidemiology, Pulmonary disease, prevalence, Risk factors
1.
American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(suppl 5):77S–120S.
2.
Pauwels RA, Buist AS, Ma P, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive summary. Am J Respir Crit Care Med 2001;46:798–825.
3.
Web page: www.goldcopd.com.
4.
Hurd S: The impact of COPD on lung health worldwide, epidemiology and incidence. Chest 2000;117(suppl 2):1S–4S.
5.
Lundbäck B, Gulsvik A, Albers M, et al: Epidemiological aspects and early detection of chronic obstructive airway diseases in elderly. Eur Respir J 2003;21(suppl 40):3S–9S.
6.
Lacasse Y, Brooks D, Goldstein, RS: Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. Chest 1999;116:306–313.
7.
Calverley PM: COPD: Early detection and intervention. Chest 2000;117(5 suppl 2):365S–371S.
8.
Mannino DM: COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 suppl):121S–126S.
9.
Rennard S, Decramer M, Calverley PM, et al: Impact of COPD in North America and Europe in 2000: Subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799–805.
10.
Murray CJL, Lopez AD: Alternative visions of the future: Projecting mortality and disability, 1990–2020; in Murray CJL, Lopez AD (eds): The Global Burden of Disease. Publication from the Harvard School of Public Health, on behalf of the World Health Organization and the World Bank. Cambridge, Harvard University Press, 1996, pp 361–395.
11.
Gulsvik A: The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis 2001;56/3:261–264.
12.
Viegi G, Scognamiglio A, Baldacci S, et al: Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001;68/1:4–19.
13.
Siafkas NM, Vermiere P, Pride NB, et al: ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398–1420.
14.
British Thoracic Society: BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(suppl 5):1S–28S.
15.
Halbert RJ, Isonaka S, George D, et al: Interpreting COPD prevalence estimates. What is the true burden of disease? Chest 2003;123:1684–1692.
16.
Lange P, Groth S, Nyboe GJ, et al: Effects of smoking and changes in smoking habits on the decline of FEV1. Copenhagen City Heart Study. Eur Respir J 1989;2:811–816.
17.
Bakke PS, Baste V, Hanoa R, et al: Prevalence of obstructive lung disease in a general population: Relation to occupational title and exposure to some airborne agents. Thorax 1991;46:863–870.
18.
Sobradillo V, Miravitlles M, Jimenez CA, et al: Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): Prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol 1999;35/4:159–166.
19.
Mannino DM, Gahnon RC, Petty TL, et al: Obstructive lung disease and low lung function in adults in the United States. Data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2000;160:1683–1989.
20.
Lundbäck B, Lindberg A, Lindström M, et al: Not 15 but 50% of smokers develop COPD? – Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97/2:115–122.
21.
Lundbäck B, Nyström, L, Rosenhal L, et al: Obstructive lung disease in northern Sweden: Respiratory symptoms assessed in a postal survey. Eur Respir J 1991;4:257–266.
22.
Larsson LG, Lindberg A, Franklin KA, et al: Obstructive sleep apnoea syndrome is common in subjects with chronic bronchitis. Report from the Obstructive Lung Disease in Northern Sweden studies. Respiration 2001;68/3:250–255.
23.
Lindström M, Kotaniemi J, Jönsson E, et al: Smoking, respiratory symptoms, and diseases: A comparative study between northern Sweden and northern Finland – A report from the FinEsS study. Chest 2001;119:852–861.
24.
Pallasaho P, Lundbäck B, Laspa SL, et al: Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinEsS-Helsinki Study. Respir Med 1999;93:798–809.
25.
Medical Research Council’s Committee on Aetiology of Chronic Bronchitis – Standardised questionnaires on respiratory symptoms. Br Med J 1960;ii:1665.
26.
Lebowitz MD, Knudson RJ, Burrows B: Tucson epidemiologic study of obstructive lung diseases. I. Methodology and prevalence of disease. Am J Epidemiol 1975;102/2:137–152.
27.
Burney PG, Laitinen LA, Perdrizet S, et al: Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: An international comparison. Eur Respir J 1989;2:940–945.
28.
ATS statement – Snowbird workshop on standardisation of spirometry. Am Rev Respir Dis 1979;119:831–838.
29.
Berglund E, Birath G, Grimby G, et al: Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963;173:185–192.
30.
Lundbäck B, Stjernberg N, Nyström L, et al: Epidemiology of respiratory symptoms, lung function and important determinants. Report from the Obstructive Lung Disease in Northern Sweden Project. Tuber Lung Dis 1994;75:116–126.
31.
Quanjer PH, Tammeling GJ, Cotes JE, et al: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests. European Community for Coal and Steel. Eur Respir J Suppl 1993;16:5S–40S.
32.
American Thoracic Society: Evaluation of impairment/disability secondary to respiratory disorders. Am Rev Respir Dis 1986;133:1205–1209.
33.
Viegi G, Pedreschi M, Pistelli F, et al: Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000;117(5 suppl 2):339S–345S.
34.
Pena VC, Miravitlls M, Gabriel R, et al: Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981–989.
35.
Hardie JA, Buist AS, Vollmer WM, et al: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002;20:1117–1122.
36.
Celli B, Halbert RJ, Isonaka S, et al: Population impact of different definitions of airway obstruction. Eur Respir J 2003;22:268–273.
37.
Jaakkola MS: Chronic obstructive pulmonary disease in Finland: Occurrence and determinants. Eur Respir J 2000;10(review 75):448–453.
38.
Pistelli F, Bottai M, Viegi G, et al: Smooth reference equations for slow vital capacity and flow-volume curve indexes. Am Rev Crit Care Med 2000;161:899–905.
39.
Sherman CB, Xu X, Speizer FE, et al: Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992;146:855–859.
40.
Vestbo J, Prescott E, Lange P: Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530–1535.
41.
Vestbo J, Lange P: Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002;166:329–332.
42.
Chapman KR, Tashkin DP, Pye DJ: Gender bias in the diagnosis of COPD. Chest 2001;119:1691–1695.
43.
van den Boom G, van Schayck CP, van Mollen MP, et al: Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730–1738.
44.
Kornman O, Beeh KM, Beier J, et al: Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration 2003;70:67–75.
45.
Scanlon PD, Connett JE, Waller LA, et al: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381–390.
46.
Soriano JB, Maier WC, Egger P, et al: Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789–794.
47.
Xu X, Weiss ST, Rijken B, et al: Smoking, changes in smoking habits, and rate of decline in FEV1: New insight into gender differences. Eur Respir J 1994;7:1056–1061.
48.
Prescott E, Bjerg AM, Andersen PK, et al: Gender difference in smoking effects on lung function and risk of hospitalization for COPD: Results from a Danish longitudinal population study. Eur Respir J 1997;10:822–827.
49.
Langhammer A, Johnsen R, Gulsvik A, et al: Sex differences in lung vulnerability to tobacco smoking. Eur Respir J 2003;21:1017–1023.
50.
Silverman EK, Weiss ST, Drazen JM, et al: Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:2152–2158.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.